Amgen Inc. (AMGN) Stock Analysis
Amgen Inc. is one of the world's largest independent biotechnology companies, discovering and manufacturing human therapeutics across oncology, cardiovascular, immunology, and bone health. Investors research AMGN for its diversified drug portfolio, consistent dividend payments, and exposure to aging-population healthcare trends.
Get a full AI research report on AMGN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Amgen Inc. do?
Amgen discovers, develops, manufactures, and distributes prescription pharmaceuticals globally, with blockbuster products including Enbrel (rheumatoid arthritis), Repatha (cardiovascular), Prolia (osteoporosis), and KYPROLIS (multiple myeloma). The company generates revenue primarily through direct sales of branded biologics and small-molecule drugs to hospitals, physicians, and patients, supported by a strong gross margin of 71.9% that reflects the pricing power of patented therapeutics.
Bull case
- ✓Forward P/E of 15.8 suggests the stock trades at a discount to its trailing P/E of 24.0, potentially indicating market pessimism that could present value for long-term holders.
- ✓Operating margin of 35.5% and net margin of 23.0% demonstrate substantial profitability and efficient conversion of revenue to earnings, typical of successful branded pharmaceutical companies.
- ✓Dividend yield of 2.6% with a payout ratio of 60.9% indicates sustainable cash returns to shareholders while retaining capital for R&D and acquisitions.
- ✓Diversified product portfolio across multiple therapeutic areas and geographies reduces dependence on any single drug or market, lowering concentration risk.
Bear case
- ✗Debt-to-equity ratio of 490.3 is extremely high, indicating the company carries substantial leverage relative to shareholder equity, which constrains financial flexibility and increases refinancing risk.
- ✗PEG ratio of 2.32 suggests the stock may be trading at a premium relative to expected earnings growth, warranting scrutiny of pipeline success and revenue growth assumptions.
- ✗Pharmaceutical companies face ongoing patent cliff risks as blockbuster drugs lose exclusivity; Amgen's future growth depends on successful new product launches and pipeline advancement.
- ✗Quick ratio of 0.95 indicates potential liquidity constraints in the near term, as current liabilities nearly match liquid assets, which could limit operational agility during downturns.
AMGN valuation & financial health
Amgen trades at a trailing P/E of 24.0 and forward P/E of 15.8, suggesting the market prices in near-term headwinds but expects earnings recovery. The company's 71.9% gross margin and 35.5% operating margin reflect the economics of branded biologics, while a 23.0% net margin shows strong bottom-line conversion. However, the debt-to-equity ratio of 490.3 is a significant concern, indicating the balance sheet is heavily leveraged; this is partially offset by a current ratio of 1.37, though the quick ratio of 0.95 suggests tighter short-term liquidity. Return on equity of 91.5% is exceptionally high, though this reflects the leverage effect rather than pure operational efficiency. The PEG ratio of 2.32 warrants monitoring of pipeline execution to justify current valuations.
The bottom line
Amgen presents a mixed profile for investors to weigh. On one hand, the company's diversified blockbuster portfolio, strong margins, and sustainable dividend appeal to income-focused and value-oriented investors; the forward P/E discount to trailing multiples may signal an opportunity if earnings growth accelerates. On the other hand, the extreme leverage (490 debt-to-equity), patent cliff exposure, and modest liquidity position introduce material risks that require careful monitoring of pipeline progress, debt refinancing, and competitive pressures. Key factors to monitor include upcoming clinical trial results, biosimilar competition, patent expirations, and management's capital allocation strategy.
Frequently asked questions
What does Amgen Inc. do?
Amgen discovers, develops, manufactures, and distributes human therapeutics worldwide, with a focus on oncology, cardiovascular disease, immunology, and bone health. The company markets blockbuster drugs like Enbrel, Repatha, and Prolia to hospitals, physicians, and patients globally.
Is AMGN a good stock to research?
AMGN is a large-cap biotech company suitable for research by income and value investors interested in healthcare exposure. Its diversified portfolio, strong margins, and dividend history make it a common holding, though the high leverage and patent cliff risks warrant thorough due diligence.
Is AMGN overvalued or undervalued?
The forward P/E of 15.8 is lower than the trailing P/E of 24.0, suggesting the market may be pricing in near-term challenges; however, the PEG ratio of 2.32 indicates the stock trades at a premium relative to growth expectations. Valuation depends on your assumptions about pipeline success and earnings trajectory.
What are Amgen's main products?
Key products include Enbrel (rheumatoid arthritis), Repatha (cardiovascular), Prolia (osteoporosis), KYPROLIS (multiple myeloma), Otezla (psoriasis), XGEVA (bone health), and TEPEZZA (thyroid eye disease), among others.
What is Amgen's dividend yield?
Amgen's dividend yield is 2.6% with a payout ratio of 60.9%, indicating the company returns a meaningful portion of earnings to shareholders while retaining capital for R&D and strategic investments.
What are the main risks for AMGN investors?
Key risks include high debt-to-equity leverage (490.3), patent expirations on blockbuster drugs, biosimilar competition, pipeline execution risk, and tight short-term liquidity (quick ratio 0.95). Monitoring debt refinancing and clinical trial outcomes is essential.
Research AMGN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.